Research ArticleClinical Studies
Angiogenic Markers in Plasma Cell Myeloma Patients Treated with Novel Agents
MICHAEL MEDINGER, JÖRG HALTER, DOMINIK HEIM, ANDREAS BUSER, SABINE GERULL, MARTIN STERN and JAKOB PASSWEG
Anticancer Research February 2015, 35 (2) 1085-1090;
MICHAEL MEDINGER
Division of Hematology, University Hospital Basel, Basel, Switzerland
JÖRG HALTER
Division of Hematology, University Hospital Basel, Basel, Switzerland
DOMINIK HEIM
Division of Hematology, University Hospital Basel, Basel, Switzerland
ANDREAS BUSER
Division of Hematology, University Hospital Basel, Basel, Switzerland
SABINE GERULL
Division of Hematology, University Hospital Basel, Basel, Switzerland
MARTIN STERN
Division of Hematology, University Hospital Basel, Basel, Switzerland
JAKOB PASSWEG
Division of Hematology, University Hospital Basel, Basel, Switzerland
In this issue
Anticancer Research
Vol. 35, Issue 2
February 2015
Angiogenic Markers in Plasma Cell Myeloma Patients Treated with Novel Agents
MICHAEL MEDINGER, JÖRG HALTER, DOMINIK HEIM, ANDREAS BUSER, SABINE GERULL, MARTIN STERN, JAKOB PASSWEG
Anticancer Research Feb 2015, 35 (2) 1085-1090;
Jump to section
Related Articles
- No related articles found.
Cited By...
- bFGF Polymorphism Is Associated with Disease Progression and Response to Chemotherapy in Multiple Myeloma Patients
- Gene-expression Profiling in Patients with Plasma Cell Myeloma Treated with Novel Agents
- Immunoglobulin G (IgG) Subtype Is Associated with a Favorable Survival Prognosis in Patients Irradiated for Spinal Cord Compression from Myeloma
- Therapeutic Potential of Thalidomide and Its Analogues in the Treatment of Cancer